Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker

Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice

(2019) Abdus Sattar Bhuiyan et al.   HYPERTENSION RESEARCH

Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study

(2019) Mitsuhiro Nishimoto et al.   HYPERTENSION RESEARCH

Esaxerenone: First Global Approval

(2019) Sean Duggan   DRUGS

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria

(2019) Sadayoshi Ito et al.   Clinical Journal of the American Society of Nephrology

Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study

(2019) Hiroshi Itoh et al.   HYPERTENSION RESEARCH

Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension

(2019) Hiromi Rakugi et al.   HYPERTENSION RESEARCH

Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)

(2019) Sadayoshi Ito et al.   HYPERTENSION

Update on Diabetic Nephropathy: Core Curriculum 2018

(2018) Kausik Umanath et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease

(2018) Akira Nishiyama   HYPERTENSION RESEARCH

Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats

(2018) Lei Li et al.   HYPERTENSION RESEARCH

A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy

(2017) Shigehiro Katayama et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

(2017) Peter Kolkhof et al.   JOURNAL OF ENDOCRINOLOGY

Analytics of oxidative stress markers in the early diagnosis of oxygen DNA damage

(2017) Natalia Dabrowska et al.   Advances in Clinical and Experimental Medicine

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis

(2017) Greg H. Tesch et al.   Frontiers in Pharmacology

Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension

(2016) Shigeru Shibata et al.   HYPERTENSION RESEARCH

Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys

(2016) Makiko Yamada et al.   XENOBIOTICA

Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Potassium Handling with Dual Renin-Angiotensin System Inhibition in Diabetic Nephropathy

(2014) P. N. Van Buren et al.   Clinical Journal of the American Society of Nephrology

Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy

(2013) Thomas A. Mavrakanas et al.   European Journal of Internal Medicine

Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study

(2013) Kazuaki Shimamoto et al.   HYPERTENSION RESEARCH